WINDLAS — Windlas Biotech Balance Sheet
0.000.00%
- IN₹17.20bn
- IN₹14.90bn
- IN₹7.60bn
- 86
- 25
- 51
- 57
Annual balance sheet for Windlas Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 545 | 1,787 | 1,320 | 2,045 | 2,395 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 835 | 1,171 | 1,174 | 1,377 | 2,011 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,943 | 3,817 | 3,535 | 4,313 | 5,251 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 955 | 983 | 1,227 | 1,803 | 2,219 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,961 | 4,910 | 5,290 | 6,262 | 7,605 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 934 | 940 | 1,212 | 1,718 | 2,494 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 970 | 962 | 1,267 | 1,763 | 2,547 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 1,991 | 3,948 | 4,023 | 4,499 | 5,058 |
| Total Liabilities & Shareholders' Equity | 2,961 | 4,910 | 5,290 | 6,262 | 7,605 |
| Total Common Shares Outstanding |